DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA III
Recent Volumes in this Series

Volume 448
COPPER TRANSPORT AND ITS DISORDERS: Molecular and Cellular Aspects
Edited by Arturo Leone and Julian F. B. Mercer

Volume 449
VASOPRESSIN AND OXYTOCIN: Molecular, Cellular, and Clinical Advances
Edited by Hans H. Zingg, Charles W. Bourque, and Daniel G. Bichet

Volume 450
ADVANCES IN MODELING AND CONTROL OF VENTILATION
Edited by Richard L. Hughson, David A. Cunningham, and James Duffin

Volume 451
GENE THERAPY OF CANCER
Edited by Peter Walden, Uwe Trefzer, Wolfram Sterry, and Farzin Farzaneh

Volume 452
MECHANISMS OF LYMPHOCYTE ACTIVATION AND IMMUNE REGULATION VII: Molecular Determinants of Microbial Immunity
Edited by Sudhir Gupta, Alan Sher, and Rafi Ahmed

Volume 453
MECHANISMS OF WORK PRODUCTION AND WORK ABSORPTION IN MUSCLE
Edited by Haruo Sugi and Gerald H. Pollack

Volume 454
OXYGEN TRANSPORT TO TISSUE XX
Edited by Antal G. Hudetz and Duane F. Bruley

Volume 455
RHEUMADERM: Current Issues in Rheumatology and Dermatology
Edited by Carmel Mallia and Jouni Uitto

Volume 456
RESOLVING THE ANTIBIOTIC PARADOX: Progress in Understanding Drug Resistance and Development of New Antibiotics
Edited by Barry P. Rosen and Shahriar Mobashery

Volume 457
DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA III
Edited by G. J. L. Kaspers, R. Pieters, and A. J. P. Veerman

A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.
DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA III

Edited by
G. J. L. Kaspers
R. Pieters and
A. J. P. Veerman

University Hospital Vrije Universiteit
Amsterdam, The Netherlands
PREFACE

Cellular drug resistance is a major limitation to the success of chemotherapy of leukemia and lymphoma. The importance of this has now been recognized by both clinicians and scientists. It is of utmost importance to bridge the gap between laboratory and clinic in this field of research. This is the main purpose of the series of International Symposia on Drug Resistance in Leukemia and Lymphoma. These are held every three years in Amsterdam, The Netherlands, since 1992. This book contains the proceedings of the third of these meetings, organised in 1998.

The book covers all important aspects of drug resistance in leukemia and lymphoma, both in the form of extensive reviews as in manuscripts describing original data. General mechanisms of resistance are discussed, including the drug resistance related proteins p-glycoprotein, MRP (multi-drug resistance protein) and LRP (lung resistance protein), and the role of glutathione and glutathione-S-transferases. Moreover, more drug type-specific mechanisms of resistance are a topic, such as for glucocorticoids and antifolates. Much information is provided on apoptosis and its regulators, and on the results of cell culture drug resistance assays. Several papers focus on the modulation or circumvention of drug resistance.

All together, the book contains more than 60 chapters with an extensive amount of information on all aspects of drug resistance in leukemia and lymphoma. It can be recommended to scientists, laboratory researchers, and clinicians.
CONTENTS

Section I. Drug Resistance Related Proteins and Glutathione

1. MDR1/P-gp Expression as a Prognostic Factor in Acute Leukemias ........... 1
   Jean-Pierre Marie and Ollivier Legrand

2. Clinical Significance of P-Glycoprotein (P-gp) Expression in Childhood Acute
   Lymphoblastic Leukemia: Results of a 6-Year Prospective Study .......... 11
   Catharina Dhooge and Barbara De Moerloose

3. Prognostic Value of P-gp Expression and Related Function in Childhood Acute
   Leukemia ................................................. 21
   Z. Karakaş, L. Ağaoğlu, S. Erdem, G. Yanikkaya Demirel, M. Arasa,
   F. Süzergöz, G. Deniz, S. Anak, and G. Gedikoğlu

4. Comparison of P-Glycoprotein Expression and Function with in Vitro Sensitivity
   to Anthracyclines in AML .................................. 29
   Alena W. Elgie, Jean M. Sargent, Christine J. Williamson,
   Grazyna M. Lewandowicz, and Colin G. Taylor

5. Quinine Improves Results of Intensive Chemotherapy (IC) in Myelodysplastic
   Syndromes (MDS) Expressing P-Glycoprotein (PGP): Updated Results of
   a Randomized Study ........................................ 35
   E. Wattel, E. Solary, B. Hequet, D. Caillot, N. Ifrah, A. Brion, N. Milpied,
   M. Janvier, A. Guerci, H. Rochant, C. Cordonnier, F. Dreyfus, A. Veil,
   L. Hoang-Ngoc, A. M. Stoppa, N. Gratecos, A. Sadoun, H. Tilly, P. Brice,
   B. Lioure, B. Desablens, B. Pignon, J. P. Abgrall, M. Leporrier,
   B. Dupriez, D. Guyotat, P. Lepelley, and P. Fenaux

6. Treatment of Poor Prognosis AML Patients Using PSC833 (Valspodar) plus
   Mitoxantrone, Etoposide, and Cytarabine (PSC-MEC) ................... 47
   R. Advani, G. Visani, D. Milligan, H. Saba, M. Tallman, J. M. Rowe,
   P. H. Wiernik, J. Ramek, K. Dugan, B. Lum, J. Villena, E. Davis,
   E. Paietta, M. Litchman, A. Covelli, B. Sikic, and P. Greenberg
7. Assessment of P-Glycoprotein Expression by Immunocytochemistry and Flow
Cytometry Using Two Different Monoclonal Antibodies Coupled with
Functional Efflux Analysis in 34 Patients with Acute
Myeloid Leukemia .................................................. 57
S. Poulain, P. Lepelley, N. Cambier, A. Cosson, P. Fenaux, and E. Wattel

8. Preliminary Immunocytochemical Studies of MDR-1 and MDR-3 Pgp
Expression in B-Cell Leukaemias .................................. 65
Annemarie Larkin, Elizabeth Moran, Denis Alexander, and Martin Clynes

9. A Mutation in the Promoter of the Multidrug Resistance Gene (MDR1) in
Human Hematological Malignancies May Contribute to the Pathogenesis
of Resistant Disease ........................................... 71
Deborah Rund, Idit Azar, and Olga Shperling

10. Reproducible Flow Cytometric Methodology for Measuring Multidrug
Resistance in Leukaemic Blasts .................................... 77
M. Pallis, J. Turzanski, S. Langabeer, and N. H. Russell

11. Natural Fluorescence Imaging of Leukemic Cells for Studying Uptake and
Retention of Anthracyclines ........................................ 89
M. Monici, F. Fusi, P. Mazzinghi, A. Degli Innocenti o Nocentini,
I. Landini, I. Banchelli, B. Bartolozzi, V. Santini, and P. A. Bernabei

12. Artificial Neural Networks as Versatile Tools for Prediction of
MDR-Modulatory Activity .......................................... 95
C. Tmej, P. Chiba, K.-J. Schaper, G. Ecker, and W. Fleischhacker

13. Discordance of P-Glycoprotein Expression and Function in Acute Leukemia ... 107
Barbara De Moerloose, Catharina Dhooge, and Jan Philippé

14. Multidrug Resistance Related Proteins in Primary Cutaneous Lymphomas ... 119
Christian W. van Haselen, Marcel J. Flens, Rik J. Scheper,
Paul van der Valk, George L. Scheffer, Johan Toonstra, and
Willem A. van Vloten

15. The Lung Resistance Protein (LRP) Predicts Poor Outcome in Acute Myeloid
Leukemia ........................................................... 133
Robert Pirker, Gudrun Pohl, Thomas Stranzl, Ralf W. Suchomel,
Rik J. Scheper, Ulrich Jäger, Klaus Geissler, Klaus Lechner, and
Martin Filipits

16. MRP Expression in Acute Myeloid Leukemia: An Update .......................... 141
Martin Filipits, Thomas Stranzl, Gudrun Pohl, Ralf W. Suchomel, Sabine
Zöchbauer, Raoul Brunner, Klaus Lechner, and Robert Pirker

17. Evidence for Functional Discrimination between Leukemic Cells
Overexpressing Multidrug-Resistance Associated Protein and
P-Glycoprotein .................................................... 151
Zineb Benderra, Hamid Morjani, Aurélie Trussardi, and Michel Manfait
18. Both Pgp and MRP1 Activities Using Calcein-AM Contribute to Drug Resistance in AML ............................................ 161
Ollivier Legrand, Ghislaine Simonin, Jean-Yves Perrot, Robert Zittoun, and Jean-Pierre Marie

19. Absolute Levels of MDR-1, MRP, and BCL-2 mRNA and Tumor Remission in Acute Leukemia .............................................. 177
T. Köhler, S. Leiblein, S. Borchert, J. Eller, A.-K. Rost, D. Laßner, R. Krahl, W. Helbig, O. Wagner, and H. Remke

20. Multidrug Resistance Protein MRP1, Glutathione, and Related Enzymes: Their Importance in Acute Myeloid Leukemia ...................... 187
Dorina M. van der Kolk, Edo Vellenga, Michael Müller, and Elisabeth G. E. de Vries

21. Glutathione and the Regulation of Cell Death ........................................ 199
A. G. Hall

22. Evidence for the Involvement of the Glutathione Pathway in Drug Resistance in AML ....................................................... 205
J. M. Sargent, C. Williamson, A. G. Hall, A. W. Elgie, and C. G. Taylor

23. Glutathione in Childhood Acute Leukaemias ........................................ 211

Section II. Apoptosis and Cell Death Regulations

Marina Konopleva, Shourong Zhao, Zhong Xie, Harry Segall, Anas Younes, David F. Claxton, Zeev Estrov, Steven M. Kornblau, and Michael Andreeff

25. Activation of Apoptosis Pathways by Anticancer Drugs ...................... 237
Klaus-Michael Debatin

26. BCL-2 Stimulates Apoptin®-Induced Apoptosis ................................ 245
Astrid A. A. M. Danen-Van Oorschot, Alex J. van der Eb, and Mathieu H. M. Notebom

27. CD95 (Fas/Apo-1) Antigen Is a New Prognostic Marker of Blast Cells of Acute Lymphoblastic Leukaemia Patients ........................................ 251

28. Inhibition of Fas/Fas-Ligand Does Not Block Chemotherapy-Induced Apoptosis in Drug Sensitive and Resistant Cells ...................... 259
Deborah S. Richardson, Paul D. Allen, Stephen M. Kelsey, and Adrian C. Newland
29. Effects of PARP Inhibition on Drug and FAS-Induced Apoptosis in Leukaemic Cells
Deborah S. Richardson, Paul D. Allen, Stephen M. Kelsey, and Adrian C. Newland

267

30. Apoptotic Fraction in Childhood ALL Assessed by DNA in Situ Labelling Is Ploidy Independent
Allen F. Pyesmany, Lynne M. Ball, Margaret Yhap, M. Henry, Krista Laybolt, D. Christie Riddell, and Dick van Velzen

281

31. PCNA Bearing Structures Are Retained in Apoptotic Phase of Childhood ALL Cell Cycle
Lynne M. Ball, Christopher L. Lannon, Margaret Yhap, Allen F. Pyesmany, M. Henry, Krista Laybolt, D. Christie Riddell, and Dick van Velzen

289

32. Apoptosis Corrected Proliferation Fraction in Childhood ALL Is Related to Karyotype
Lynne M. Ball, Allen F. Pyesmany, Margaret Yhap, Christopher L. Lannon, M. Henry, Krista Laybolt, D. Christie Riddell, and Dick van Velzen

297

33. Proliferation and Apoptosis Does Not Affect Presenting White Cell Count in Childhood ALL
Allen F. Pyesmany, Lynne M. Ball, Margaret Yhap, M. Henry, Krista Laybolt, D. Christie Riddell, and Dick van Velzen

305

34. Apoptosis by Anthracyclines at Therapeutic Concentrations in MDR1+ Human Leukemic Cells
Barbara Chiodini, Renato Bassan, and Tiziano Barbui

313

35. BCL-2 Expression in Childhood Leukemia versus Spontaneous Apoptosis, Drug Induced Apoptosis and in Vitro Drug Resistance

325

36. Comparison of BCL-2 and Bax Protein Expression with in Vitro Sensitivity to Ara-C and 6TG in AML
S. E. Balkham, J. M. Sargent, A. W. Elgie, C. J. Williamson, and C. G. Taylor

335

37. Synthetic Cyclin Dependent Kinase Inhibitors: New Generation of Potent Anti-Cancer Drugs
Marián Hajdúch, Libor Havlíček, Jaroslav Veselý, Radko Novotný, Vladimir Mihál, and Miroslav Strnád

341

38. Factors Contributing to the Resistance to Apoptosis Induced by Topoisomerase I Inhibitors in Vincristine Resistant Cells
Valérie Palissot, Aurélie Trussardi, Marie-Claude Gorisse, and Jean Dufer

355

39. Two Distinct Modes of Oncoprotein Expression during Apoptosis Resistance in Vincristine and Daunorubicin Multidrug-Resistant HL60 Cells
Rajae Belhoussine, Hamid Morjani, Reynald Gillet, Valérie Palissot, and Michel Manfait

365
### Section III. Risk Factors and Cell Culture Assays

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>40. Genetic Abnormalities and Drug Resistance in Acute Lymphoblastic Leukemia</td>
<td>383</td>
</tr>
<tr>
<td>Ching-Hon Pui and William E. Evans</td>
<td></td>
</tr>
<tr>
<td>Studies from Amsterdam</td>
<td></td>
</tr>
<tr>
<td>R. Pieters, G. J. L. Kaspers, N. L. Ramakers-van Woerden, M. L. den Boer,</td>
<td></td>
</tr>
<tr>
<td>M. G. Rots, Ch. M. Zwaan, E. G. Haarman, and A. J. P. Veerman</td>
<td></td>
</tr>
<tr>
<td>42. Pharmacokinetics of Anticancer Drugs in Vitro</td>
<td>397</td>
</tr>
<tr>
<td>Alexandra Wagner, Georg Hempel, Gumbinger H. G., Heribert Jürgens, and</td>
<td></td>
</tr>
<tr>
<td>Joachim Boos</td>
<td></td>
</tr>
<tr>
<td>43. Down Syndrome and Acute Myeloid Leukemia: Lessons Learned from</td>
<td>409</td>
</tr>
<tr>
<td>Experience with High-Dose Ara-C Containing Regimens</td>
<td></td>
</tr>
<tr>
<td>Yaddanapudi Ravindranath and Jeffrey W. Taub</td>
<td></td>
</tr>
<tr>
<td>44. Cellular Drug Resistance in Childhood Acute Myeloid Leukemia:</td>
<td>415</td>
</tr>
<tr>
<td>A Mini-Review with Emphasis on Cell Culture Assays</td>
<td></td>
</tr>
<tr>
<td>G. J. L. Kaspers, Ch. M. Zwaan, R. Pieters, and A. J. P. Veerman</td>
<td></td>
</tr>
<tr>
<td>45. Is in Vitro Sensitivity of Blast Cells Correlated to Therapeutic Effect in Childhood Acute Lymphoblastic Leukemia?</td>
<td>423</td>
</tr>
<tr>
<td>Britt-Marie Frost, Rolf Larsson, Peter Nygren, and Gudmar Lönnerholm</td>
<td></td>
</tr>
<tr>
<td>46. In Vitro Cytotoxic Drug Activity and in Vivo Pharmacokinetics in Childhood Acute Myeloid Leukemia</td>
<td>429</td>
</tr>
<tr>
<td>Gudmar Lönnerholm, Britt-Marie Frost, Rolf Larsson, E. Liliemark,</td>
<td></td>
</tr>
<tr>
<td>Peter Nygren, and Curt Peterson</td>
<td></td>
</tr>
<tr>
<td>47. Prognosis in Adult AML Is Precisely Predicted by the Disc-Assay Using the Chemosensitivity-Index Ĉ</td>
<td>437</td>
</tr>
<tr>
<td>Peter Staib, Bernd Lathan, Timo Schinköthe, Sabine Wiedenmann,</td>
<td></td>
</tr>
<tr>
<td>Bernhard Pantke, Thomas Dimski, Dimitris Voliotis, and Volker Diehl</td>
<td></td>
</tr>
<tr>
<td>48. Drug Resistance Testing of Acute Myeloid Leukemia in Adults Using the MTT Assay</td>
<td>445</td>
</tr>
<tr>
<td>N. Stute, T. Köhler, L. Lehmann, W. Wetzstein, and G. Ehninger</td>
<td></td>
</tr>
<tr>
<td>49. MTT Assay for Drug Resistance in Childhood Acute Leukemia and Effect of Cyclosporin and Interferon: A Preliminary Report</td>
<td>453</td>
</tr>
<tr>
<td>Zeynep Karakaş, Leyla Ağaoğlu, Serap Erdem, Sema Anak,</td>
<td></td>
</tr>
<tr>
<td>Ayşegül Hacibektasoğlu, and Gündüz Gedikoğlu</td>
<td></td>
</tr>
<tr>
<td>50. Differential Antileukemic Activity of Prednisolone and Dexamethasone in Freshly Isolated Leukemic Cells</td>
<td>459</td>
</tr>
<tr>
<td>Vladimír Mihál, Marián Hajdúch, Věra Nosková, Gabriela Feketová,</td>
<td></td>
</tr>
<tr>
<td>Kassmine Jess, Libuše Gojová, Ivo Kašpárek, Jan Starý, Bohumír Blažek,</td>
<td></td>
</tr>
<tr>
<td>Dagmar Pospíšilová, and Zbyník Novák</td>
<td></td>
</tr>
</tbody>
</table>
51. Activity of Vinorelbine on B-Chronic Lymphocytic Leukemia Cells in Vitro  . . . 473
    P. A. Bernabei, I. Landini, B. Bartolozzi, I. Banchelli,
    A. Degli Innocenti o Nocentini, and V. Santini

52. Studies of Some Mechanisms of Drug Resistance in Chronic Myeloid Leukemia
    (CML) ...................................................... 477
    Anna G. Turkina, Natalia P. Logacheva, Tatjana P. Stromskaya,
    Tatjana N. Zabotina, Sergei V. Kuznetzov, Kuralay K. Sachibzadaeva,
    Akshin Tagiev, Vacheslav S. Juravlev, Nina D. Khoroshko,
    Anatoly Y. Baryshnikov, and Alla A. Stavrovskaya

53. Clinical Sensitivity to Anthracyclines in Ph/BCR+ Acute Lymphoblastic
    Leukemia .......................................................... 489
    Renato Bassan, Ama Z. S. Rohatiner, Alessandro Rambaldi, Teresa Lerede,
    Eros Di Bona, Maxine Carter, Giuseppe Rossi, Enrico Pogliani,
    Giorgio Lambertenghi-Deliliers, Piero Fabris, Adolfo Porcellini,
    T. Andrew Lister, and Tiziano Barbui

54. Differential Kinetics of Drug Resistance in Human Leukaemic Cells Measured
    by SCGE/CLSM .................................................. 501
    Lynne M. Ball, Christopher L. Lannon, G. Ross Langley, Allen F. Pyesmany,
    Margaret Yhap, and Dick van Velzen

55. Demonstration of Differences in Drug Resistance by Direct Testing of DNA
    Excision Repair Activity following Standard and Liposomal Daunorubicin
    Exposure in Normal Paediatric Marrow Using High Resolution CLSM . . . 509
    Christopher L. Lannon, Lynne M. Ball, Allen F. Pyesmany, Margaret Yhap,
    G. Ross Langley, and Dick van Velzen

56. Microsatellite Instability Assessment in Prediction of Drug Resistance in
    Childhood Burkitt’s and Large Cell Diffuse Malignant Non-Hodgkin
    Lymphoma (MNHL) .................................................. 517
    Margaret Yhap, Allen F. Pyesmany, Lynne M. Ball, D. Christie Riddle,
    Jiang Mu, and Dick van Velzen

57. High Resolution Confocal Laser Scanning Microscopy Analysis of DNA
    Excision Repair Capability in Small Volume Marrow Samples Exposed to
    DNA Directed Treatment Moieties .................................. 527
    Christopher L. Lannon, Lynne M. Ball, Allen F. Pyesmany, Margaret Yhap,
    Ross Langley, and Dick van Velzen

Section IV. Antifolates

58. Defining the Optimal Dosage of Methotrexate for Childhood Acute
    Lymphoblastic Leukemia: New Insights from the Lab and Clinic ........... 537
    William E. Evans, Ching-Hon Pui, and Mary V. Relling
59. Mechanisms of Methotrexate Resistance in Acute Leukemia:
   Decreased Transport and Polyglutamylation ........................ 543
   Richard Gorlick, Peter Cole, Debabrata Banerjee, Giuseppe Longo,
   Wei Wei Li, Daniel Hochhauser, and Joseph R. Bertino

60. Lack of Cross-Resistance between Prednisolone and Methotrexate in Childhood
   Acute Lymphoblastic Leukemia? A Preliminary Analysis ............. 551
   I. R. H. J. Hegge, G. J. L. Kaspers, M. G. Rots, G. Jansen, R. Pieters, and
   A. J. P. Veerman

Section V. Nucleoside Analogues and Growth Factors

61. New Developments in the Treatment of Acute Myeloid Leukemia .......... 557
   Marielle Smeets, Theo de Witte, Netty van der Lely, Reinier Raymakers, and
   Petra Muus

62. Aphidicolin Markedly Increases the in Vitro Sensitivity to Ara-C of Blast Cells
   from Patients with AML ........................................ 567
   J. M. Sargent, A. W. Elgie, C. J. Williamson, and C. G. Taylor

63. Common Resistance Mechanisms to Nucleoside Analogues in Variants of the
   Human Erythroleukemic Line K562 .................................... 571
   Charles Dumontet, Evelyne Callet Bauchu, Krystyna Fabianowska,
   Michel Lepoivre, Dorota Wyczewichowska, Frédérique Bodin, and
   Marie Odile Rolland

64. Expression of DNA Mismatch Repair Proteins in Acute Lymphoblastic
   Leukaemia and Normal Bone Marrow .................................. 579
   E. C. Matheson and A. G. Hall

65. Effects of CSFS and Their Combinations with Chemotherapeutic Agents (Ch)
   on Leukemic Blasts (LB) in Children (MTT-Assay) .................. 585
   E. Litvinova, K. Gurova, K. Chimishkian, and G. Mentkevich

Section VI. Glucocorticoids

66. Glucocorticosteroid Therapy in Childhood Acute Lymphoblastic Leukemia ... 593
   Paul S. Gaynon and Aaron L. Carrel

67. Glucocorticoid Induced Apoptosis in Leukemia .......................... 607
   Lou A. Smets, Gajja Salomons, and Joop van den Berg

68. Glucocorticoid Resistance and the AP-1 Transcription Factor in Leukemia .... 615
   S. Bailey, A. G. Hall, A. D. J. P. Pearson, M. M. Reid, and C. P. F. Redfern
Section VII. Asparaginase

69. The Three Asparaginases: Comparative Pharmacology and Optimal Use in Childhood Leukemia ......................................................... 621
   Barbara L. Asselin

Index ........................................................................................................... 631